Hisun drops license option after ThermoDox HCC failure but door still ajar
This article was originally published in Clinica
Executive Summary
Following the missed primary endpoint in Celsion's Phase III HEAT trial with its ThermoDox technology in hepatocellular carcinoma (HCC), the US firm's Chinese partner Hisun Pharmaceutical has decided to not to pursue an option deal for the licensing of the product.
You may also be interested in...
Chinese Appetite For Medtech Could Shrink In Face Of Uncertainty
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China’s Big And Small Next-Gen Sequencing Players Ride The Precision Medicine Wave
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
China's new biosimilars guideline: more flexibility, but stricter in parts
The China Food and Drug Administration has released the final version of its biosimilars guideline1.